Author:
Huemer F.,Weiss L.,Regitnig P.,Winder T.,Schmitt C.A.,Thaler J.,Wöll E.,Greil R.
Reference6 articles.
1. Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer-results from the AGMT GASTRIC-5 registry;Huemer;J Clin Med,2020
2. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study;Haffner;J Clin Oncol,2021
3. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial;Yamaguchi;J Clin Oncol,2023
4. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma;Nakayama;ESMO Open,2023
5. HER2-low expression in patients with advanced or metastatic solid tumors;Uzunparmak;Ann Oncol,2023